Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Bibliography

• Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006;2:159-66
   PubMedGoogle Scholar
• Luchsinger JA, Reitz C, Honig LS, Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65:545-51
   PubMed Web of Science ®Google Scholar
• Xu WL, Qiu CX, Wahlin A, Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004;63:1181-6
   PubMed Web of Science ®Google Scholar
• Xu WL, Von SE, Qiu CX, Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009;52:1031-9
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187-92
   PubMed Web of Science ®Google Scholar
• Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003;8:815-23
   PubMed Web of Science ®Google Scholar
• Yaffe K, Blackwell T, Kanaya AM, Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-63
   PubMed Web of Science ®Google Scholar
• Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 2005;48:2460-9
   PubMed Web of Science ®Google Scholar
• Janson J, Laedtke T, Parisi JE, Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-81
   PubMed Web of Science ®Google Scholar
• Craft S, Asthana S, Cook DG, Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003;28:809-22
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256-62
   PubMed Web of Science ®Google Scholar
• Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004;47:157-69
   PubMed Web of Science ®Google Scholar
• Kompoti M, Mariolis A, Alevizos A, Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes. Cardiovasc Diabetol 2006;5:21
   PubMedGoogle Scholar
• Cole SL, Grudzien A, Manhart IO, Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 2005;280:18755-70
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007;4:147-52
   PubMed Web of Science ®Google Scholar
• Holscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 2010;84:331-54
   PubMed Web of Science ®Google Scholar
• Kaiyala KJ, Prigeon RL, Kahn SE, Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000;49:1525-33
   PubMed Web of Science ®Google Scholar
• Zhao WQ, Chen H, Quon MJ, Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004;490:71-81
   PubMed Web of Science ®Google Scholar
• Steen E, Terry BM, Rivera EJ, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80
   PubMed Web of Science ®Google Scholar
• Park CR, Seeley RJ, Craft S, Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000;68:509-14
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH, Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-8
   PubMed Web of Science ®Google Scholar
• Kulstad JJ, Green PS, Cook DG, Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006;66:1506-10
   PubMed Web of Science ®Google Scholar
• Watson GS, Peskind ER, Asthana S, Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003;60:1899-903
   PubMed Web of Science ®Google Scholar
• Qiu WQ, Walsh DM, Ye Z, Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-8
   PubMed Web of Science ®Google Scholar
• Cole AR, Astell A, Green C, Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007;31:1046-63
   PubMed Web of Science ®Google Scholar
• Freude S, Plum L, Schnitker J, Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005;54:3343-8
   PubMed Web of Science ®Google Scholar
• Leahy JL, Cooper HE, Deal DA, Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986;77:908-15
   Google Scholar
• O'Donnell N, Zachara NE, Hart GW, Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol 2004;24:1680-90
   PubMedGoogle Scholar
• Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007;56:384-402
   PubMedGoogle Scholar
• Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-44
   PubMed Web of Science ®Google Scholar
• Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704-7
   PubMed Web of Science ®Google Scholar
• Yada T, Itoh K, Nakata M. Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3′,5′-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity. Endocrinology 1993;133:1685-92
   PubMedGoogle Scholar
• Mingrone G, Nolfe G, Castagneto GG, Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia 2009;52:873-81
   PubMed Web of Science ®Google Scholar
• Balks HJ, Holst JJ, Von zur MA, Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 1997;82:786-90
   PubMed Web of Science ®Google Scholar
• Elliott RM, Morgan LM, Tredger JA, Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159-66
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39
   PubMed Web of Science ®Google Scholar
• Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004;36:842-5
   PubMedGoogle Scholar
• Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005;21:313-31
   PubMed Web of Science ®Google Scholar
• Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 1998;35:117-29
   PubMedGoogle Scholar
• Goke R, Larsen PJ, Mikkelsen JD, Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300
   PubMed Web of Science ®Google Scholar
• Shughrue PJ, Lane MV, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996;137:5159-62
   PubMed Web of Science ®Google Scholar
• Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-24
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14
   PubMed Web of Science ®Google Scholar
• Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004;490:5-12
   PubMed Web of Science ®Google Scholar
• Lerche S, Brock B, Rungby J, Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 2008;57:325-31
   PubMedGoogle Scholar
• Perfetti R, Zhou J, Doyle ME, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-5
   PubMed Web of Science ®Google Scholar
• During MJ, Cao L, Zuzga DS, Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-9
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Chen D, A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66
   PubMed Web of Science ®Google Scholar
• Perry T, Haughey NJ, Mattson MP, Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-8
   PubMed Web of Science ®Google Scholar
• Perry T, Holloway HW, Weerasuriya A, Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301
   PubMed Web of Science ®Google Scholar
• Harkavyi A, Abuirmeileh A, Lever R, Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008;5:19
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Patrone C, Zachrisson O, Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008;86:326-38
   PubMed Web of Science ®Google Scholar
• Li Y, Perry T, Kindy MS, GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009;106:1285-90
   PubMed Web of Science ®Google Scholar
• Mora F, Exposito I, Sanz B, Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7–36) amide in the basal ganglia of the conscious rat. Brain Res Bull 1992;29:359-61
   PubMedGoogle Scholar
• Calvo JC, Gisolfi CV, Blazquez E, Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Brain Res Bull 1995;38:435-9
   PubMedGoogle Scholar
• Oka JI, Goto N, Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 1999;10:1643-6
   PubMed Web of Science ®Google Scholar
• Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009;205:265-71
   PubMed Web of Science ®Google Scholar
• Gault VA, Porter WD, Flatt PR, Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int J Obes (Lond) 2010;34:1341-4
   PubMedGoogle Scholar
• Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98
   PubMed Web of Science ®Google Scholar
• Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000;343:411-19
   PubMed Web of Science ®Google Scholar
• Kahn SE, D'Alessio DA, Schwartz MW, Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 1990;39:634-8
   PubMed Web of Science ®Google Scholar
• Opie EL. The relation of diabetes mellitus to lesions of the pancreas. hyaline degeneration of the islands of Langerhans. J Exp Med 1901;5:527-40
   PubMedGoogle Scholar
• Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
   PubMed Web of Science ®Google Scholar
• Haataja L, Gurlo T, Huang CJ, Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008;29:303-16
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-55
   PubMed Web of Science ®Google Scholar
• Chiang PK, Lam MA, Luo Y. The many faces of amyloid beta in Alzheimer's disease. Curr Mol Med 2008;8:580-4
   PubMed Web of Science ®Google Scholar
• Nitta A, Fukuta T, Hasegawa T, Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997;73:51-7
   PubMedGoogle Scholar
• Nitta A, Itoh A, Hasegawa T, beta. amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994;170:63-6
   PubMed Web of Science ®Google Scholar
• Miklossy J, Qing H, Radenovic A, Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 2010;31:1503-15
   PubMed Web of Science ®Google Scholar
• Stoltenberg M, Bush AI, Bach G, Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 2007;150:357-69
   PubMed Web of Science ®Google Scholar
• Smidt K, Jessen N, Petersen AB, SLC30A3 responds to glucose-and zinc variantions in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. PLoS One 2009;4:1-12
   Google Scholar
• Petersen AB, Smidt K, Magnusson N, Apoptosis in INS-1E cells after ZnT-3 and ZnT-8 knock-out. Diabetologia 2009;52:s152-3
   Google Scholar
• Oka J, Suzuki E, Goto N, Endogenous GLP-1 modulates hippocampal activity in beta-amyloid protein-treated rats. Neuroreport 1999;10:2961-4
   PubMedGoogle Scholar
• Oka J, Suzuki E, Kondo Y. Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats. Brain Res 2000;878:194-8
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Sambamurti K, Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603-12
   PubMed Web of Science ®Google Scholar
• Liu J, Yin F, Zheng X, Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 2007;51:361-9
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng X, Yin F, Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int J Dev Neurosci 2006;24:419-24
   PubMed Web of Science ®Google Scholar
• Liu JH, Yin F, Guo LX, Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 2009;30:159-65
   PubMed Web of Science ®Google Scholar
• Qin Z, Sun Z, Huang J, Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett 2008;444:217-21
   PubMedGoogle Scholar
• Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008;587:112-17
   PubMed Web of Science ®Google Scholar
• McClean PL, Gault VA, Harriott P, Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158-62
   PubMed Web of Science ®Google Scholar
• Gengler S, McClean PL, McCurtin R, Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010; punblished online 31 March 2010; doi:10.1016/j.neurobiolaging. 2010.02.014
   PubMedGoogle Scholar
• Li Y, Duffy KB, Ottinger MA, GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010;19:1205-19
   PubMed Web of Science ®Google Scholar
• D'Amico M, Di FC, Marfella R, Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010;45:202-7
   PubMed Web of Science ®Google Scholar
• Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004;5:565-71
   PubMed Web of Science ®Google Scholar
• Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011;27:547-58
   PubMed Web of Science ®Google Scholar
• Rossor MN. Neurotransmitters and CNS disease. Dementia. Lancet 1982;2:1200-4
   PubMedGoogle Scholar
• Moreira PI, Zhu X, Nunomura A, Therapeutic options in Alzheimer's disease. Expert Rev Neurother 2006;6:897-910
   PubMedGoogle Scholar